The #HF21 Series presented by @CanHFSociety is back, the fall edition launches on September 9! Don’t miss the opportunity to ask your questions to the faculty of experts: Dr. Grace Chua, Dr. @ShelleyZieroth and Dr. Lisa Mielniczuk will be presenting the first 3 episodes. https://t.co/WFBzWxDwbz

Don't miss part 1 of the accredited @CanHFSociety series on Top 3 HF Conundrums! The 2-part series kicks off TONIGHT with Dr @ShelleyZieroth and Dr @AniqueDucharme. Part 2 with Dr @JustinEzekowitz takes place on September 14. Details and registration at https://t.co/K0kOhWNbh2 https://t.co/vzdj3Np8ds

Don't miss tonight's live episode - Aug. 31 at 7pm. Part 1: Top 3 Heart Failure Conundrums. Section 1 accredited! @SCC_CCS @CanHFSociety Register at https://t.co/BM7DbzqRKU ! https://t.co/bIopLxUAfm

Finerenone furthers benefits seen in Fidelio in milder T2D with eGFR>60, UACR>30, with MACE⬇️13%, driven by 29%⬇️HF Hosp, balanced by 1.2% disc’n due to ⬆️K vs 0.4%. Shows further cardiorenal X-protection @UOHIResearch @JavedButler1 @CanHFSociety @ShelleyZieroth https://t.co/g0hoTXff9D

Overall , it is a big day for patients living with HFpEF, a big day for HF clinicians @ShelleyZieroth @JavedButler1 @Steph_Achenbach @rahatheart1 @NMHheartdoc @AndrewJSauer @mvaduganathan @HFA_President @lamcardio @EkateriniL @DrMarthaGulati @biljana_parapid #ESCCongress @Hragy https://t.co/PUEBS2jt3v

#EMPEROR-P ?IC/☠️CV ⤵️RR 21% ?HF⤵️RR 27% ?eGFR slope +1.36ml/min ⬆️KCCQ & NYHA ?no effect total mortality ? The benefit of empagliflozin on the primary endpoint was consistent across all pre-specified subgroups, including LVEF, sex and diabetes #ESCCongress @secardiologia https://t.co/GVZlRxIW3h

NEW: #ESCGuidelines for Diagnosis and Treatment for Acute and Chronic #HeartFailure https://t.co/H4SfiIATIJ Algorithm for the treatment of patients with advanced #HF ? Do you know how to select patients with advanced heart failure for mechanical support? ? #ESCCongress https://t.co/icefFeqLDd

Our wonderful Twitter Ambassadors @MajaCikes @paomorejon @ShelleyZieroth @hvanspall @MihaiTrofenciuc @HanCardiomd @pabeda1 are ready to give you all the new #HF science during #ESCCongress Follow their updates ? #Heartteam https://t.co/ilXkcmT3lY https://t.co/e1KyLraxE2

Key aspects to watch #EMPERORPreserved #ESC2021 LateBreaker ❓ Magnitude of benefit on primary endpt ❓ Effect on CVd ❓ Heterogeneity by LVEF These ?s will determine if #SGLT2i will rise above other #GDMT that have class I (in HFrEF), class II (in HFmrEF), & no rec (in HFpEF). https://t.co/V36cn9vN5Q

Did you know the @CanHFSociety has developed an #hf admission #orderset? Did you know that use of order sets reduce LOS, readmissions, and mortality? Get a copy of #hforderset at https://t.co/Wk0adX3awf and register for the live webinars on https://t.co/TTNTNGSdJ6. https://t.co/SrAJHMqDmw